GlassScriptPhysician profile
John P Moran
NPI 1255430823
$1,965.04
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $802 · 2021: $147.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $279.47 | 2019-2020 | |
| Amgen INC. | $243.50 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $139.62 | 2019-2020 | |
| Pfizer INC. | $130.97 | 2019-2020 | |
| Medtronic USA, INC. | $129.73 | 2019-2020 | |
| Lilly USA, LLC | $118.11 | 2019-2021 | |
| Sk Life Science, INC. | $109.60 | 2020-2021 | |
| Ucb, INC. | $102.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $97.99 | 2019-2020 | |
| Abbvie INC. | $93.45 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.30 | 2019 | |
| Genzyme Corporation | $46.51 | 2019-2020 | |
| Novo Nordisk INC | $40.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.24 | 2019 | |
| Astellas Pharma US INC | $37.25 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.84 | 2019-2020 | |
| Ge Healthcare | $32.26 | 2019 | |
| Lundbeck LLC | $29.45 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $28.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.96 | 2019 | |
| Boston Scientific Corporation | $21.27 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.28 | 2020 | |
| Abbott Laboratories | $17.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.43 | 2019 | |
| Amarin Pharma, INC. | $16.10 | 2019 | |
| Acorda Therapeutics, INC | $16.01 | 2020 | |
| Neurocrine Biosciences, INC. | $14.30 | 2020 | |
| Sunovion Pharmaceuticals INC. | $13.17 | 2019 | |
| Smith+Nephew, INC. | $11.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.